Martin Reck

机构：German Center for Lung Research, LungenClinic Grosshansdorf · ORCID：0000-0002-5348-4462

发表论文 633 篇 · 总被引 55014 次 · h-index 92

代表论文

• Unresectable stage III non-small-cell lung cancer: state of the art and challenges (2025 · Nature Reviews Clinical Oncology · 被引 14)
• Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study (2025 · The Lancet Oncology · 被引 9)
• First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study (2025 · Journal of Thoracic Oncology · 被引 9)
• Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671 (2025 · The Annals of Thoracic Surgery · 被引 8)
• Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design (2025 · Future Oncology · 被引 5)
• Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations (2025 · Nature Communications · 被引 4)